daclizumab


Also found in: Wikipedia.

daclizumab

 [dah-kliz´u-mab]
an immunosuppressant used to prevent acute organ rejection in renal transplant patients; administered intravenously.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

daclizumab

Dacliximab, Zenapax® Transplant medicine A monoclonal antibody used with other agents to ↓ transplant-related GVHD and organ rejection in kidney and liver graft recipients, and Pts with treatment refractory psoriasis, uveitis, tropical spastic paraparesis and some leukemias. See Kidney transplant.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.

daclizumab

A humanized monoclonal antibody against the interleukin-2 receptor. It is used to decrease the risk of organ rejection in kidney and heart transplants.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
In contrast, the frequency of FOXP3+ T cells declines to almost undetectable level after induction with the nondepleting anti-CD25 antibody daclizumab. In terms of absolute counts, however, all induction strategies induced a sustained drop in the first month, and there was no recovery of FOXP3+ T cell counts for at least 12 months of observation [49].
M2 EQUITYBITES-August 10, 2011-Biogen Idec and Abbott announce positive top-line results from SELCT trial for Daclizumab HYP in RRMS(C)2011 M2 COMMUNICATIONS http://www.m2.com
began a Phase III study of their lead drug, daclizumab, for MS in May
The compounds include daclizumab - a Phase II investigational biologic intended to treat multiple sclerosis (MS) that is expected to move into Phase III development in the second quarter 2010 - and oncology compounds in early- to mid-stage development.
Efros et al., "Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis," Multiple Sclerosis Journal, 2013.
Over the last two decades a number of drugs, including immunomodulatory and immunosuppressive agents such as interferon-[beta], glatiramer acetate, and the monoclonal antibodies such as natalizumab and daclizumab have shown beneficial effects in patients with MS.
In a study comparing a corticosteroids-free regimen of tacrolimus, MMF and daclizumab induction therapy with tacrolimus, and MMF and corticosteroids, Rostaing et al.
Patients received induction therapy with rATG (Thymoglobulin, Genzyme) or daclizumab (Zenapax, Roche) in a case of PRA > 50% and 20%, respectively.
T-cell depleting antibodies like antithymocyte globulin (ATG) or muromonab-CD3 (OKT3) as well as interleukin-2 (IL-2) receptor specific antibodies like basiliximab or daclizumab are widely used to induce graft tolerance, but their impact on PTLD development is difficult to estimate [31].
demonstrated in a pilot study that treatment with daclizumab, a humanized anti-CD25 therapeutic mAb, depletes Treg and correlates with enhanced immunity in glioblastoma patients [20].
Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory acute GVHD.
Antibodies, such as alemtuzumab (targets CD-52 antigen), infliximab (targets TNF), and daclizumab (targets CD-25), have been successfully used in various refractory cases (1).